Back to today’s briefing

Story perspectives

FDA Faces New Challenges Over Mifepristone Access Debate

5/26/2025

23 4

Summary

Story summary

The FDA's previous expansion of mifepristone access faces new challenges as officials like Marty Makary raise concerns. A controversial EPPC report, lacking scientific backing, labels the drug as dangerous, clashing with robust research affirming its safety. Meanwhile, anti-abortion advocates push to restrict access, ignoring the wealth of evidence supporting mifepristone's use.

1 of 1

Story summary

The FDA's previous expansion of mifepristone access faces new challenges as officials like Marty Makary raise concerns. A controversial EPPC report, lacking scientific backing, labels the drug as dangerous, clashing with robust research affirming its safety. Meanwhile, anti-abortion advocates push to restrict access, ignoring the wealth of evidence supporting mifepristone's use.